Tackling bias in AI health datasets through the STANDING Together initiative. Correspondence from Xiaoxuan Liu Denniston_Ophth and colleagues unibirmingham
K.H., A.K., N.R. and S.R.P. are employees of Google. S.K. is a consultant for Hardian Health. D.T. and F.M. are funded by National Pathology Imaging Co-operative , which is supported by a £50 million investment from the Data to Early Diagnosis and Precision Medicine strand of the government’s Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation . X.L., A.K.D., J.E.A. and J.P.
receives funding from the NIHR, UK Research and Innovation , NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR ARC West Midlands, UK SPINE, European Regional Development Fund – Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK , Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead, has received personal fees from Astellas, Aparito...
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
When insulin isn’t enough: targeting glucagon in type 1 diabetes - Nature MedicineA phase 2 study fails to meet its primary endpoint, but the treatment — a glucagon receptor antagonist — shows clinically relevant improvements in glycemic control, warranting further investigation as a potential adjunct to insulin.
Lire la suite »
Metabolomic profiles predict individual multidisease outcomes - Nature MedicineIn a study involving more than 100,000 individuals in the UKBiobank, a NeuralNetwork model trained on Metabolomic data can predict disease risk for over 20 conditions and adds predictive information over clinical variables for eight common diseases.
Lire la suite »
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial - Nature MedicineA phase 2 study testing glucagon receptor antagonist volagidemab as an adjunct to insulin therapy in patients was found to be safe and tolerable. Although the primary endpoint of reduction in daily insulin usage was not met, volagidemab therapy was associated with improved glycaemic control compared to placebo.
Lire la suite »
Buried treasure of 44 Byzantine gold coins found in nature reserve in IsraelMost of the coins were minted during Emperor Heraclius' reign.
Lire la suite »
Universal control of a six-qubit quantum processor in silicon - NatureThe universal control of six qubits in a 28Si/SiGe quantum dot array is demonstrated, achieving Rabi oscillations for each qubit with visibilities of 93.5–98.0%, implying high readout and initialization fidelities.
Lire la suite »
The Winners of the 2022 Nature Conservancy Photo ContestThe Nature Conservancy has announced the winners of its 2022 Photo Contest featuring images of landscapes, people, climate, and more.
Lire la suite »